Cyanokit(hydroxocobalamin)
Cyanokit, Hydroxocobalamin (hydroxocobalamin) is a small molecule pharmaceutical. Hydroxocobalamin was first approved as Hydroxocobalamin on 1982-01-01. It is used to treat alcoholic neuropathy, diabetic neuropathies, multiple sclerosis, pernicious anemia, and poisoning in the USA. It has been approved in Europe to treat poisoning.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Cyanokit, Hydroxocobalamin (discontinued: Alpharedisol, Cyanokit, Hydroxocobalamin, Hydroxomin)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aronamin gold | unapproved drug other | 2018-12-12 |
| cyanokit | New Drug Application | 2023-04-27 |
| hydroxocobalamin | ANDA | 2020-01-18 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B03: Antianemic preparations
— B03B: Vitamin b12 and folic acid
— B03BA: Vitamin b12 (cyanocobalamin and analogues)
— B03BA03: Hydroxocobalamin
— B03BA53: Hydroxocobalamin, combinations
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AB: Antidotes
— V03AB33: Hydroxocobalamin
HCPCS
No data
Clinical
Clinical Trials
717 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vitamin b 12 deficiency | D014806 | EFO_0000734 | E53.8 | 2 | 4 | 2 | 5 | 48 | 59 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | 4 | 8 | 5 | 36 | 51 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 2 | 2 | 2 | 11 | 17 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | 1 | 3 | 2 | 1 | 10 | 16 |
| Hyperhomocysteinemia | D020138 | — | — | — | 1 | 2 | 1 | 12 | 16 |
| Cognitive dysfunction | D060825 | — | G31.84 | 1 | 4 | — | 1 | 10 | 16 |
| Iron deficiencies | D000090463 | — | E61.1 | — | 1 | 1 | 2 | 13 | 16 |
| Iron-deficiency anemia | D018798 | — | D50 | — | — | — | 3 | 12 | 15 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 4 | 3 | 2 | 7 | 14 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 1 | — | 2 | 9 | 13 |
Show 61 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 15 | 9 | — | 3 | 26 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | 2 | 3 | — | 17 | 21 |
| Avitaminosis | D001361 | EFO_0005878 | E56.9 | — | 2 | 4 | — | 12 | 16 |
| Covid-19 | D000086382 | — | U07.1 | 1 | 2 | 3 | — | 8 | 13 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 3 | 1 | — | 10 | 13 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | 2 | — | 8 | 11 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | 9 | 2 | — | — | 10 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | 1 | — | 9 | 10 |
| Depression | D003863 | — | F33.9 | — | 2 | 1 | — | 8 | 10 |
| Peripheral nervous system diseases | D010523 | — | G64 | 1 | 3 | 1 | — | 5 | 9 |
Show 86 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | 2 | — | — | 11 | 14 |
| Recurrence | D012008 | — | — | 6 | 5 | — | — | — | 9 |
| Brain injuries | D001930 | — | S06.9 | 2 | 1 | — | — | 3 | 5 |
| Aging | D000375 | GO_0007568 | R41.81 | — | 1 | — | — | 4 | 5 |
| Micronutrients | D018977 | — | — | — | 1 | — | — | 4 | 5 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | 2 | 1 | — | — | 3 | 5 |
| Hepatitis | D006505 | — | K75.9 | — | 3 | — | — | 1 | 4 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | 3 | — | — | 1 | 4 |
| Memory disorders | D008569 | — | — | — | 1 | — | — | 3 | 4 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | 1 | 1 | — | — | 2 | 3 |
Show 74 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammation | D007249 | MP_0001845 | — | 1 | — | — | — | 13 | 14 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | 4 | 5 |
| Weight loss | D015431 | — | — | 1 | — | — | — | 4 | 5 |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | — | — | — | 3 | 4 |
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | 2 | 3 |
| Child development | D002657 | — | — | 1 | — | — | — | 2 | 3 |
| Sezary syndrome | D012751 | — | C84.1 | 2 | — | — | — | — | 2 |
| Mycosis fungoides | D009182 | — | C84.0 | 2 | — | — | — | — | 2 |
| T-cell lymphoma cutaneous | D016410 | — | C84.A | 2 | — | — | — | — | 2 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | — | — | — | 1 | 2 |
Show 15 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Folic acid deficiency | D005494 | EFO_0001070 | E53.8 | — | — | — | — | 12 | 12 |
| Deglutition disorders | D003680 | — | R13.1 | — | — | — | — | 9 | 9 |
| Gyrate atrophy | D015799 | — | — | — | — | — | — | 6 | 6 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 6 | 6 |
| Vitamin a deficiency | D014802 | EFO_1001237 | E50 | — | — | — | — | 6 | 6 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | — | — | 6 | 6 |
| Fatigue | D005221 | — | R53.83 | — | — | — | — | 5 | 5 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 4 | 4 |
| Nutritional status | D009752 | — | — | — | — | — | — | 4 | 4 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | — | — | — | 4 | 4 |
Show 223 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Hydroxocobalamin |
| INN | hydroxocobalamin |
| Description | Hydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is a vitamin found in food and used as a dietary supplement. As a supplement it is used to treat vitamin B12 deficiency including pernicious anemia. Other uses include treatment for cyanide poisoning, Leber's optic atrophy, and toxic amblyopia. It is given by injection into a muscle or vein.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 13422-51-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2103737 |
| ChEBI ID | 27786 |
| PubChem CID | 44475014 |
| DrugBank | DB00200 |
| UNII ID | Q40X8H422O (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Hydroxocobalamin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,739 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
668 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use